Datasheet

IL-27 Antibody
CATALOG NUMBER: 3799

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Pig: (92%)
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:IL-27 antibody can be used for the detection of IL-27 by Western blot at 2 - 4 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1224 - Daudi Cell Lysate
IMMUNOGEN:IL-27 antibody was raised against a 14 amino acid synthetic peptide from near the center of human IL-27.

The immunogen is located within amino acids 80 - 130 of IL-27.
HOST SPECIES:Rabbit

Properties

PURIFICATION:IL-27 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:IL-27 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:IL-27 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:IL-27 Antibody: p28, IL30, IL-27, IL27A, IL-27A, IL27p28, Interleukin-27 subunit alpha, p28, IL-27 subunit alpha
ACCESSION NO.:NP_663634
PROTEIN GI NO.:28416913
OFFICIAL SYMBOL:IL27
GENE ID:246778

Background

BACKGROUND:IL-27 Antibody: Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naïve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet.
REFERENCES: 1) Pfanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naïve CD4(+) T cells. Immunity 2002; 16:779-90.
2) Pfanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 2004; 172:2225-31.
3) Hisada M, Kamiya S, Fujita K, et al. Potent antitumor activity of interleukin-27. Cancer Res. 2004; 64:1152-6

For Research Use Only